Search results for "docking"

showing 10 items of 299 documents

Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.

2019

Estrogens play a key role in cellular proliferation of estrogen-receptor-positive (ER+) breast cancers (BCs). Suppression of estrogen production by competitive inhibitors of the enzyme aromatase (AIs) is currently one of the most effective therapies against ER + BC. Yet, the development of acquired resistance, after prolonged treatments with AIs, represents a clinical major concern. Serendipitous findings indicate that aromatase may be non-competitively inhibited by clinically employed drugs and/or industrial chemicals. Here, by performing in silico screening on two putative allosteric sites, molecular dynamics and free energy simulations, supported by enzymatic and cell-based assays, we id…

Molecular dynamicmedicine.drug_classIn silicoAllosteric regulationCytochromes P450; Aromatase; Molecular dynamics; Aromatase inhibitors; Docking; Breast cancer; Resistance onset; Mixed inhibition mechanismAntineoplastic AgentsBreast NeoplasmsMolecular dynamicsMolecular Dynamics SimulationDockingStructure-Activity RelationshipBreast cancerBreast cancerAromataseAllosteric RegulationCell Line TumorDrug DiscoverymedicineResistance onsetHumansMixed inhibition mechanismAromataseEnzyme InhibitorsCell ProliferationPharmacologychemistry.chemical_classificationbiologyDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryRational designAromatase inhibitorGeneral Medicinemedicine.diseaseEnzymeAromatase inhibitorsSettore CHIM/03 - Chimica Generale E InorganicaEstrogenDocking (molecular)Drug Designbiology.proteinCancer researchDrug Screening Assays AntitumorCytochromes P450European journal of medicinal chemistry
researchProduct

Suitability ofMMGBSAfor the selection of correct ligand binding modes from docking results

2018

The estimation of the correct binding mode and affinity of a ligand into a target protein using computational methods is challenging. However, docking can introduce poses from which the correct binding mode could be identified using other methods. Here, we analyzed the reliability of binding energy estimation using the molecular mechanics-generalized Born surface area (MMGBSA) method without and with energy minimization to identify the likely ligand binding modes within docking results. MMGBSA workflow (a) outperformed docking in recognizing the correct binding modes of androgen receptor ligands and (b) improved the correlation coefficient of computational and experimental results of rescor…

Molecular modelBinding energyta3111LigandsEnergy minimization01 natural sciencesBiochemistrylääkesuunnitteluSubstrate SpecificityCytochrome P-450 CYP2A6Free energy perturbationCoumarinsDrug DiscoveryHumansta317PharmacologyBinding Sitesmolecular modeling010405 organic chemistryChemistryDrug discoveryOrganic Chemistryta1182liganditreceptor and ligandslaskennallinen kemiaLigand (biochemistry)Protein Structure Tertiary0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistryDocking (molecular)structure based drug-designThermodynamicsMolecular MedicineproteiinitTarget proteinBiological systemProtein BindingChemical Biology & Drug Design
researchProduct

New potent antibacterials against Gram-positive multiresistant pathogens: effects of side chain modification and chirality in linezolid-like 1,2,4-ox…

2014

The effects of side chain modification and chirality in linezolid-like 1,2,4-oxadiazoles have been studied to design new potent antibacterials against Gram-positive multidrug-resistant pathogens. The adopted strategy involved a molecular modelling approach, the synthesis and biological evaluation of new designed compounds, enantiomers separation and absolute configuration assignment. Experimental determination of the antibacterial activity of the designed (S)-1-((3-(4-(3-methyl-1,2,4-oxadiazol-5- yl)phenyl)-oxazolidin-2-one-5-yl)methyl)-3-methylthiourea and (S)-1-((3-(3-fluoro-4-(3-methyl-1,2,4- oxadiazol-5-yl)phenyl)-oxazolidin-2-one-5-yl)methyl)-3-methylthiourea against multidrug resistan…

Multidrug-resistant bacteriaClinical BiochemistryAntibioticsDrug ResistanceMolecular ConformationPharmaceutical ScienceBiochemistrychemistry.chemical_compoundAntibioticsDrug Resistance Multiple BacterialDrug DiscoveryAcetamidesSide chainOxadiazolesAbsolute configurationBacterialStereoisomerismHep G2 CellsBIO/10 - BIOCHIMICA23SAnti-Bacterial AgentsMolecular Docking SimulationRNA Ribosomal 23SDrug design Linezolid Antibiotics Multidrug-resistant bacteria EnantiomersMolecular MedicineAntibacterial activityMultipleMethicillin-Resistant Staphylococcus aureusStaphylococcus aureusmedicine.drug_classStereochemistryCell SurvivalMicrobial Sensitivity TestsGram-Positive BacteriaDrug designmedicineHumansMolecular BiologyOxazolidinonesRibosomalBinding SitesOrganic ChemistryAntibioticLinezolidSettore CHIM/06 - Chimica OrganicaSettore CHIM/08 - Chimica FarmaceuticaMultiple drug resistancechemistryEnantiomersMED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICALinezolidRNANucleic Acid ConformationEnantiomerChirality (chemistry)Bioorganicmedicinal chemistry
researchProduct

The crystal structure of a 250-kDa heterotetrameric particle explains inhibition of sheddase meprin β by endogenous fetuin-B

2021

Meprin β (Mβ) is a multidomain type-I membrane metallopeptidase that sheds membrane-anchored substrates, releasing their soluble forms. Fetuin-B (FB) is its only known endogenous protein inhibitor. Herein, we analyzed the interaction between the ectodomain of Mβ (MβΔC) and FB, which stabilizes the enzyme and inhibits it with subnanomolar affinity. The MβΔC:FB crystal structure reveals a ∼250-kDa, ∼160-Å polyglycosylated heterotetrameric particle with a remarkable glycan structure. Two FB moieties insert like wedges through a “CPDCP trunk” and two hairpins into the respective peptidase catalytic domains, blocking the catalytic zinc ions through an “aspartate switch” mechanism. Uniquely, the …

Multiprotein complexMetallopeptidaseCleavage (embryo)Cell LineMiceProtein structureAnimalsHumansEctoprotein sheddingProtease InhibitorsInhibitionBinding SitesMultidisciplinarybiologyChemistryMetallopeptidaseMetalloendopeptidasesActive siteBiological SciencesSheddaseFetuin-BLepidopteraMolecular Docking SimulationTransmembrane domainEctodomainbiology.proteinBiophysicsProtein structureMultiprotein complexAlzheimer’s diseaseProtein Binding
researchProduct

Deciphering the Potential of Pre and Pro-Vitamin D of Mushrooms against Mpro and PLpro Proteases of COVID-19: An In Silico Approach

2022

Vitamin D’s role in combating the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus causing COVID-19, has been established in unveiling viable inhibitors of COVID-19. The current study investigated the role of pre and pro-vitamin D bioactives from edible mushrooms against Mpro and PLpro proteases of SARS-CoV-2 by computational experiments. The bioactives of mushrooms, specifically ergosterol (provitamin D2), 7-dehydrocholesterol (provitamin-D3), 22,23-dihydroergocalciferol (provitamin-D4), cholecalciferol (vitamin-D3), and ergocalciferol (vitamin D2) were screened against Mpro and PLpro. Molecular docking analyses of the generated bioactive protease complexes unr…

Pharmaceutical Scienceedible mushroomsMolecular Dynamics SimulationViral Nonstructural ProteinsAnalytical Chemistrypro-vitamin-DErgosterolDrug DiscoveryEndopeptidasespre-vitamin-DHumansProtease InhibitorsPhysical and Theoretical ChemistryVitamin DSARS-CoV-2Organic ChemistryProvitaminsin-silico studiesSettore CHIM/08 - Chimica FarmaceuticaCOVID-19 Drug TreatmentMolecular Docking SimulationChemistry (miscellaneous)Molecular MedicineAgaricalesedible mushrooms; SARS-CoV-2; pre-vitamin-D; pro-vitamin-D; in-silico studiesPeptide HydrolasesMolecules; Volume 27; Issue 17; Pages: 5620
researchProduct

Design and Synthesis of Novel 1,3-Thiazole and 2-Hydrazinyl-1,3-Thiazole Derivatives as Anti-Candida Agents: In Vitro Antifungal Screening, Molecular…

2019

In the context of there being a limited number of clinically approved drugs for the treatment of Candida sp.-based infections, along with the rapid development of resistance to the existing antifungals, two novel series of 4-phenyl-1,3-thiazole and 2-hydrazinyl-4-phenyl-1,3-thiazole derivatives were synthesized and tested in vitro for their anti-Candida potential. Two compounds (7a and 7e) showed promising inhibitory activity against the pathogenic C. albicans strain, exhibiting substantially lower MIC values (7.81 &mu

Pharmaceutical Sciencefluorescence quenchingContext (language use)01 natural sciencesAnalytical Chemistrylcsh:QD241-44103 medical and health scienceschemistry.chemical_compoundlcsh:Organic chemistryIn vivobovine serum albuminDrug DiscoverymedicinePhysical and Theoretical ChemistryBovine serum albuminThiazole030304 developmental biology13-thiazole0303 health sciencesbiology010405 organic chemistryLanosterolOrganic Chemistryanti-<i>Candida</i>Biological activitymolecular dockingIn vitro0104 chemical scienceschemistryBiochemistryChemistry (miscellaneous)biology.proteinMolecular MedicineFluconazolemedicine.drugMolecules
researchProduct

Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors

2014

Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2\ud inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been\ud merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is\ud provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well\ud as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)-\ud N8-hydroxyoctanediamide 6.

PharmacologyHistone deacetylase 5medicine.drug_classKinaseHistone deacetylase 2Organic ChemistryHistone deacetylase inhibitorQPharmaceutical ScienceBiologyBiochemistryHDACiVEGFRiHybrids.BiochemistryDocking (molecular)In vivoDrug DiscoverymedicineMolecular MedicineHistone deacetylaseSettore BIO/06 - Anatomia Comparata E CitologiaSemaxanibmedicine.drug
researchProduct

3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors.

2010

Bcl-2 proteins family members play several roles in tumoral proliferation: they inhibit proapoptotic activity during oncogenesis, support tumor cells survival, induce chemoresistance. The discovery of new small inhibitors of Bcl-xl represents a new frontier for cancer treatment. In this study, a 3D-QSAR pharmacophore model was developed, based on 42 biarylacylsulfonamides, and used to understand the structural factors affecting the inhibitory potency of these derivatives. Aromatic, negative charge, and hydrogen bond acceptor effects contribute to the inhibitory activity. The model was then employed as 3D search query to screen ZINC drug-like database in order to select new scaffolds. Finall…

PharmacologyModels MolecularVirtual screeningQuantitative structure–activity relationshipTertiary amineMolecular modelChemistryIn silicoOrganic ChemistryMolecular Conformationbcl-X ProteinQuantitative Structure-Activity RelationshipGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaBiochemistryIn vivoDocking (molecular)Drug Discovery3D-QSAR Pharmacophore Modeling In Silico Screening Bcl-xl InhibitorsPharmacophoreEuropean journal of medicinal chemistry
researchProduct

Evaluation of the IKKβ Binding of Indicaxanthin by Induced-Fit Docking, Binding Pose Metadynamics, and Molecular Dynamics

2021

Background: Indicaxanthin, a betaxanthin belonging to the betalain class of compounds, has been recently demonstrated to exert significant antiproliferative effects inducing apoptosis of human melanoma cells through the inhibition of NF-κB as the predominant pathway. Specifically, Indicaxanthin inhibited IκBα degradation in A375 cells. In resting cells, NF-κB is arrested in the cytoplasm by binding to its inhibitor protein IκBα. Upon stimulation, IκBα is phosphorylated by the IKK complex, and degraded by the proteasome, liberating free NF-κB into the nucleus to initiate target gene transcription. Inhibition of the IKK complex leads to the arrest of the NF-κB pathway.Methods: To acquire deta…

PharmacologyMolecular modelChemistryAllosteric regulationIKKβMetadynamicsindicaxanthinInhibitor proteinRM1-950Settore CHIM/08 - Chimica Farmaceuticamolecular dynamicsIκBαchemistry.chemical_compoundanticancer activityProteasomeDocking (molecular)Settore BIO/10 - BiochimicaBiophysicsbinding pose metadynamicsPharmacology (medical)induced fit dockingTherapeutics. PharmacologyIndicaxanthinOriginal ResearchFrontiers in Pharmacology
researchProduct

Fragment- and negative image-based screening of phosphodiesterase 10A inhibitors.

2019

A novel virtual screening methodology called fragment- and negative image-based (F-NiB) screening is introduced and tested experimentally using phosphodiesterase 10A (PDE10A) as a case study. Potent PDE10A-specific small-molecule inhibitors are actively sought after for their antipsychotic and neuroprotective effects. The F-NiB combines features from both fragment-based drug discovery and negative image-based (NIB) screening methodologies to facilitate rational drug discovery. The selected structural parts of protein-bound ligand(s) are seamlessly combined with the negative image of the target's ligand-binding cavity. This cavity- and fragment-based hybrid model, namely its shape and electr…

PharmacologyVirtual screening010405 organic chemistryDrug discoveryChemistryPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesOrganic ChemistryFragment-based lead discoveryAb initioDrug Evaluation PreclinicalPhosphodiesteraseComputational biology01 natural sciencesBiochemistrySmall molecule0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistryDocking (molecular)Drug DiscoveryMolecular MedicineHumansPharmacophoreChemical biologydrug designREFERENCES
researchProduct